Quarterly report pursuant to Section 13 or 15(d)

Summary of Warrant Activity (Details)

v3.21.2
Summary of Warrant Activity (Details)
 9 Months Ended
Sep. 30, 2021
USD ($)
$ / shares
shares
Common Stock Warrants [Member]  
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Number of Warrants, Beginning Balance
Weighted Average Exercise Price, Beginning Balance | $ / shares
Weighted Average Remaining Contractual Term (years), Beginning
Aggregate Intrinsic Value, Beginning | $
Number of Warrants, Assumed from Merger 5,363,547
Weighted Average Exercise Price, Assumed from Merger | $ / shares $ 5.19
Weighted Average Remaining Contractual Term (years), Granted 5 years 7 days
Aggregate Intrinsic Value, Assumed from merger | $
Number of Warrants, Granted
Weighted Average Exercise Price, Granted | $ / shares
Weighted Average Remaining Contractual Term (years), Granted
Aggregate Intrinsic Value, Granted | $
Number of Warrants, Exercised (47,298)
Weighted Average Exercise Price, Exercised | $ / shares $ 4.12
Weighted Average Remaining Contractual Term (years), Exercised 4 years 7 months 17 days
Aggregate Intrinsic Value, Exercised | $
Number of Warrants, Forfeited
Weighted Average Exercise Price, Forfeited | $ / shares
Weighted Average Remaining Contractual Term (years), Forfeited
Aggregate Intrinsic Value, Forfeited | $
Number of Warrants, Cancelled/Expired
Weighted Average Exercise Price, Cancelled/Expired | $ / shares
Weighted Average Remaining Contractual Term (years), Canceled/Expired
Aggregate Intrinsic Value, Cancelled/Expired | $
Number of Warrants, Ending Balance 5,316,249
Weighted Average Exercise Price, Ending Balance | $ / shares $ 5.19
Weighted Average Remaining Contractual Term (years), Ending 4 years 7 months 2 days
Aggregate Intrinsic Value, Ending | $ $ 15,905,538
Number of Warrants, Exercisable 5,316,249
Weighted Average Exercise Price, Exercisable | $ / shares $ 5.19
Weighted Average Remaining Contractual Term (years), Exercisable 4 years 7 months 2 days
Aggregate Intrinsic Value, Exercisable | $ $ 15,905,538
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised 47,298
Pre-funded Common Stock Warrants [Member]  
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Number of Warrants, Beginning Balance
Weighted Average Exercise Price, Beginning Balance | $ / shares
Weighted Average Remaining Contractual Term (years), Beginning
Aggregate Intrinsic Value, Beginning | $
Number of Warrants, Assumed from Merger 986,486
Weighted Average Exercise Price, Assumed from Merger | $ / shares $ 0.002
Weighted Average Remaining Contractual Term (years), Granted
Aggregate Intrinsic Value, Assumed from merger | $
Number of Warrants, Granted
Weighted Average Exercise Price, Granted | $ / shares
Weighted Average Remaining Contractual Term (years), Granted
Aggregate Intrinsic Value, Granted | $
Number of Warrants, Exercised (466,216)
Weighted Average Exercise Price, Exercised | $ / shares $ 0.002
Weighted Average Remaining Contractual Term (years), Exercised 0 years
Aggregate Intrinsic Value, Exercised | $
Number of Warrants, Forfeited
Weighted Average Exercise Price, Forfeited | $ / shares
Aggregate Intrinsic Value, Forfeited | $
Number of Warrants, Cancelled/Expired
Weighted Average Exercise Price, Cancelled/Expired | $ / shares
Aggregate Intrinsic Value, Cancelled/Expired | $
Number of Warrants, Ending Balance 520,270
Weighted Average Exercise Price, Ending Balance | $ / shares $ 0.002
Weighted Average Remaining Contractual Term (years), Ending
Aggregate Intrinsic Value, Ending | $ $ 3,744,903
Number of Warrants, Exercisable 520,270
Weighted Average Exercise Price, Exercisable | $ / shares $ 0.002
Weighted Average Remaining Contractual Term (years), Exercisable
Aggregate Intrinsic Value, Exercisable | $ $ 3,744,903
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised 466,216
Series C Convertible Preferred Stock [Member]  
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Number of Warrants, Beginning Balance
Weighted Average Exercise Price, Beginning Balance | $ / shares
Weighted Average Remaining Contractual Term (years), Beginning 0 years
Aggregate Intrinsic Value, Beginning | $
Number of Warrants, Assumed from Merger 27,500
Weighted Average Exercise Price, Assumed from Merger | $ / shares $ 8.00
Weighted Average Remaining Contractual Term (years), Granted 3 years 7 months 24 days
Aggregate Intrinsic Value, Assumed from merger | $
Number of Warrants, Granted
Weighted Average Exercise Price, Granted | $ / shares
Weighted Average Remaining Contractual Term (years), Granted 0 years
Aggregate Intrinsic Value, Granted | $
Number of Warrants, Exercised
Weighted Average Exercise Price, Exercised | $ / shares
Weighted Average Remaining Contractual Term (years), Exercised 0 years
Aggregate Intrinsic Value, Exercised | $
Number of Warrants, Forfeited
Weighted Average Exercise Price, Forfeited | $ / shares
Weighted Average Remaining Contractual Term (years), Forfeited 0 years
Aggregate Intrinsic Value, Forfeited | $
Number of Warrants, Cancelled/Expired
Weighted Average Exercise Price, Cancelled/Expired | $ / shares
Weighted Average Remaining Contractual Term (years), Canceled/Expired 0 years
Aggregate Intrinsic Value, Cancelled/Expired | $
Number of Warrants, Ending Balance 27,500
Weighted Average Exercise Price, Ending Balance | $ / shares $ 8.00
Weighted Average Remaining Contractual Term (years), Ending 3 years 2 months 8 days
Aggregate Intrinsic Value, Ending | $
Number of Warrants, Exercisable 27,500
Weighted Average Exercise Price, Exercisable | $ / shares $ 8.00
Weighted Average Remaining Contractual Term (years), Exercisable 3 years 2 months 8 days
Aggregate Intrinsic Value, Exercisable | $
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised